Active Ingredient History
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Leukemia (Phase 2)
Multiple Myeloma (Phase 1)
Neoplasms (Phase 2)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma, Synovial (Phase 2)
Small Cell Lung Carcinoma (Phase 1/Phase 2)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue